BAX - NYSE

Baxter International Inc.

BAX·NYSE

$18.54

-1.3%

HealthcareMedical - Instruments & Supplies

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$9.58B

EPS-1.7500

P/E Ratio-10.59

Earnings Date07/30/2026

20.05B

Assets

-22%

3Y-29.0%

5Y-

10Y+29.0%

13.95B

Total Liabilities

-26%

3Y-38.0%

5Y+24.0%

10Y+92.0%

6.10B

Total Equity

-13%

3Y+4.0%

5Y-30.0%

10Y-26.0%

Baxter International Inc. Funding & Solvency Profile

BAX · NYSE

Current Assets

Cash & Cash Equivalents1.97B

Net Receivables1.93B

Inventory2.23B

Other Current Assets479.00M

Total Current Assets7 B

Non-Current Assets

Property, Plant & Equipment3.19B

Goodwill & Intangible Assets9.30B

Long-Term Investments103.00M

Other Non-Current Assets596.00M

Total Non-Current Assets4 B

Total Assets

20.05B

Financial Health Analysis

Current Ratio

2.31x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

2.29x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

4 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

34% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Baxter International Inc. Balance Sheet

BAX • NYSE

Baxter International Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	2B	1.8B	3.1B	1.7B	3B	3.7B	3.3B	1.8B	3.4B	2.8B	2.2B	2.9B	2.7B	3.3B	2.9B	2.7B	2.8B	2.1B	2.5B	2.5B
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	2B	1.8B	3.1B	1.7B	3B	3.7B	3.3B	1.8B	3.4B	2.8B	7.4B	2.9B	2.7B	3.3B	2.9B	2.7B	2.8B	2.1B	2.5B	2.5B
Net Receivables	1.9B	1.7B	1.8B	2.6B	2.7B	2.1B	1.9B	1.8B	1.8B	1.7B	1.7B	1.9B	2.9B	2.4B	2.4B	2.3B	2.3B	2B	2B	1.8B
Accounts Receivables	1.9B	1.7B	1.7B	2.6B	2.6B	2B	1.9B	1.8B	1.8B	1.7B	1.7B	1.9B	2.9B	2.4B	2.4B	2.3B	2.3B	2B	2B	1.8B
Other Receivables	0.0	51M	53M	52M	84M	70M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	2.2B	2B	1.9B	2.7B	2.5B	1.9B	1.7B	1.7B	1.5B	1.4B	1.6B	1.6B	3.5B	2.8B	2.6B	2.4B	2.6B	2.4B	2.3B	2.1B
Prepaids	261M	366M	322M	373M	365M	346M	304M	210M	233M	261M	420M	98M	548M	418M	402M	345M	400M	425M	395M	350M
Other Current Assets	479M	2.9B	2.5B	618M	390M	342M	315M	404M	368M	391M	680M	3.7B	504M	344M	295M	323M	226M	251M	261M	231M
Total Current Assets	6.9B	8.9B	9.6B	8B	8.9B	8.4B	7.5B	6B	7.3B	6.6B	11.8B	10.2B	10.2B	9.3B	8.7B	8B	8.3B	7.1B	7.6B	7B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.2B	3.2B	3.2B	5.2B	5.8B	5.3B	5.1B	4.5B	4.6B	4.3B	4.4B	4.4B	7.8B	6.1B	5.5B	5.3B	5.2B	4.6B	4.5B	4.2B
Goodwill	4.9B	5.3B	5.8B	6.5B	9.8B	3.2B	3B	3B	3.1B	2.6B	2.7B	2.9B	4.2B	2.5B	2.3B	2B	1.8B	1.7B	1.7B	1.6B
Intangible Assets	4.4B	5.2B	5.9B	6.8B	7.8B	1.7B	1.5B	1.4B	1.4B	1.1B	1.3B	1.6B	2.3B	814M	826M	500M	513M	390M	455M	480M
Goodwill & Intangible Assets	9.3B	10.5B	11.7B	13.2B	17.6B	4.9B	4.5B	4.4B	4.5B	3.7B	4B	4.5B	6.5B	3.3B	3.1B	2.5B	2.3B	2B	2.1B	2.1B
Long-Term Investments	103M	109M	136M	247M	195M	135M	76M	44M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	204M	263M	280M	376M	748M	621M	483M	408M	629M	354M	531M	41M	1.2B	1.1B	1.1B	1.1B	1.1B	689M	936M
Other Non-Current Assets	596M	2.9B	3.4B	1.3B	642M	512M	372M	292M	379M	348M	390M	6.5B	657M	560M	632M	586M	491M	472M	418M	453M
Total Non-Current Assets	13.2B	16.9B	18.7B	20.3B	24.6B	11.6B	10.7B	9.8B	9.8B	9B	9.2B	16B	15B	11.1B	10.4B	9.5B	9.1B	8.3B	7.7B	7.7B
Total Assets	20.1B	25.8B	28.3B	28.3B	33.5B	20B	18.2B	15.7B	17.1B	15.5B	21B	26.1B	25.2B	20.4B	19.1B	17.5B	17.4B	15.4B	15.3B	14.7B
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.1B	1.3B	1.2B	1.5B	1.7B	1.5B	1.2B	1.3B	1.2B	1.1B	1.5B	1.6B	2B	1.6B	1.5B	1.4B	1.4B	1.2B	1.4B	878M
Accounts Payable	999M	968M	881M	1.1B	1.2B	1B	892M	998M	920M	791M	716M	677M	1.1B	766M	795M	745M	807M	829M	920M	878M
Other Payables	88M	304M	317M	398M	404M	408M	309M	336M	315M	339M	756M	883M	885M	849M	691M	681M	549M	416M	472M	0.0
Accrued Expenses	436M	748M	783M	941M	1B	778M	803M	900M	935M	867M	826M	734M	1.3B	1.2B	1.3B	241M	1.9B	1.7B	1.9B	2.5B
Short Term Debt	84M	2.8B	2.7B	1.4B	511M	406M	541M	4M	3M	3M	2.6B	1.7B	1B	350M	446M	24M	711M	394M	425M	234M
Capital Lease Obligations (Current)	0.0	80M	92M	120M	128M	111M	101M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	217M	268M	254M	264M	283M	198M	234M	228M	269M	619M	597M	539M	603M	503M	346M	375M	255M	0.0	0.0
Deferred Revenue	141M	131M	128M	154M	162M	32M	0.0	0.0	0.0	0.0	0.0	9M	760M	878M	738M	635M	0.0	0.0	0.0	0.0
Other Current Liabilities	1.2B	1.5B	1.6B	618M	751M	555M	584M	576M	648M	744M	867M	2B	191M	755M	895M	1.7B	482M	265M	122M	0.0
Total Current Liabilities	3B	6.5B	6.5B	4.7B	4.2B	3.3B	3.2B	2.8B	2.8B	2.7B	5.8B	6B	5.2B	4.8B	4.9B	4B	4.5B	3.6B	3.8B	3.6B
NON-CURRENT LIABILITIES
Long Term Debt	9.7B	10.4B	11.1B	15.2B	17.1B	5.8B	4.8B	3.5B	3.5B	2.8B	3.9B	7.3B	8.1B	5.6B	4.7B	4.4B	3.4B	3.4B	2.7B	2.6B
Deferred Revenue (Non-Current)	36M	40M	41M	40M	84M	34M	52M	3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	245M	103M	403M	661M	962M	143M	192M	215M	280M	93M	195M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	783M	1.5B	1.5B	1.3B	1.4B	1.5B	1.5B	1.3B	1.4B	1.7B	2.2B	4.6B	3.4B	3.1B	2.6B	2.3B	2B	2.2B	1.9B	2.2B
Total Non-Current Liabilities	11B	12.2B	13.3B	17.6B	20.2B	8B	7.1B	5B	5.2B	4.5B	6.3B	11.9B	11.5B	8.7B	7.4B	6.7B	5.5B	5.5B	4.6B	4.8B
Capital Lease Obligations	244M	323M	357M	567M	650M	612M	611M	76M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	14B	18.8B	19.8B	22.4B	24.4B	11.3B	10.3B	7.9B	8B	7.3B	12.1B	18B	16.7B	13.4B	12.2B	10.7B	9.9B	9.2B	8.4B	8.4B
SHAREHOLDERS' EQUITY
Treasury Stock	-10.9B	-11.1B	-11.2B	-11.4B	-11.5B	-11.1B	-10.8B	-10B	-8B	-8B	-7.6B	-8B	-7.9B	-7.6B	-6.7B	-5.7B	-4.7B	-3.9B	-2.5B	-1.4B
Common Stock	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M	683M
Additional Paid-In Capital	6.4B	6.4B	6.4B	6.3B	6.2B	6B	6B	5.9B	5.9B	6B	5.9B	5.9B	5.8B	5.8B	5.8B	5.8B	5.7B	5.5B	5.3B	5.2B
Retained Earnings	13.7B	14.9B	16.1B	14.1B	17.1B	16.3B	15.7B	15.1B	14.5B	14.2B	9.7B	13.2B	11.9B	10.9B	9.4B	7.9B	7.3B	5.8B	4.4B	3.3B
Accumulated Other Comprehensive Income/Loss	-3.8B	-4B	-3.6B	-3.8B	-3.4B	-3.3B	-3.7B	-3.8B	-4B	-4.6B	224M	-3.7B	-2B	-2.8B	-2.6B	-2.1B	-1.8B	-1.9B	-940M	-1.4B
Total Stockholders' Equity	6.1B	7B	8.4B	5.8B	9.1B	8.7B	7.9B	7.8B	9.1B	8.3B	8.8B	8.1B	8.5B	6.9B	6.6B	6.6B	7.2B	6.2B	6.9B	6.3B
Total Equity	6.1B	7B	8.5B	5.9B	9.1B	8.7B	7.9B	7.9B	9.1B	8.3B	8.9B	8.2B	8.5B	7B	6.8B	6.8B	7.4B	6.2B	6.9B	6.3B
Minority Interest	-27M	60M	66M	62M	44M	37M	30M	22M	-8M	-10M	19M	36M	23M	40M	243M	229M	229M	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	20.1B	25.8B	28.3B	28.3B	33.5B	20B	18.2B	15.7B	17.1B	15.5B	21B	26.1B	25.2B	20.4B	19.1B	17.5B	17.4B	15.4B	15.3B	14.7B
Total Investments	103M	109M	136M	247M	195M	135M	76M	44M	0.0	0.0	5.1B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	10B	13.4B	14.1B	17.2B	18.3B	6.8B	6B	3.5B	3.5B	2.8B	6.5B	9B	9.2B	5.9B	5.2B	4.4B	4.2B	3.8B	3.1B	2.8B
Net Debt	8B	11.7B	11B	15.5B	15.4B	3.1B	2.6B	1.6B	118M	-19M	4.3B	6.1B	6.4B	2.7B	2.3B	1.7B	1.4B	1.6B	550M	316M
Shares Outstanding	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426	513,996,426

SEC Filings

BAX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 08, 2026	May 04, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 23, 2026	May 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 16, 2026	March 15, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 10, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 22, 2025	December 22, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 04, 2025	December 04, 2025	2025	View Filing

Showing 1 to 10 of 512 filings

Related Guides

Blog Categories

Continue your BAX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.